Artiva Biotherapeutics, Common Stock Number Of Shares Shorted
ARTV Stock | 5.38 0.18 3.24% |
Artiva Biotherapeutics, Common fundamentals help investors to digest information that contributes to Artiva Biotherapeutics,'s financial success or failures. It also enables traders to predict the movement of Artiva Stock. The fundamental analysis module provides a way to measure Artiva Biotherapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Artiva Biotherapeutics, stock.
Artiva | Number Of Shares Shorted |
Artiva Biotherapeutics, Common Company Number Of Shares Shorted Analysis
Artiva Biotherapeutics,'s Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Artiva Biotherapeutics, Number Of Shares Shorted | 1.25 M |
Most of Artiva Biotherapeutics,'s fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Artiva Biotherapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Artiva Number Of Shares Shorted Driver Correlations
Understanding the fundamental principles of building solid financial models for Artiva Biotherapeutics, is extremely important. It helps to project a fair market value of Artiva Stock properly, considering its historical fundamentals such as Number Of Shares Shorted. Since Artiva Biotherapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Artiva Biotherapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Artiva Biotherapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Competition |
Based on the recorded statements, Artiva Biotherapeutics, Common has 1.25 M of outstending shares currently sold short by investors. This is 60.9% lower than that of the Biotechnology sector and 75.46% lower than that of the Health Care industry. The number of shares shorted for all United States stocks is 73.41% higher than that of the company.
Artiva Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Artiva Biotherapeutics,'s direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Artiva Biotherapeutics, could also be used in its relative valuation, which is a method of valuing Artiva Biotherapeutics, by comparing valuation metrics of similar companies.Artiva Biotherapeutics, is currently under evaluation in number of shares shorted category among its peers.
Artiva Fundamentals
Return On Equity | -0.44 | ||||
Operating Margin | (23.45) % | ||||
Current Valuation | (500.63 K) | ||||
Shares Outstanding | 24.29 M | ||||
Shares Owned By Insiders | 20.64 % | ||||
Shares Owned By Institutions | 89.28 % | ||||
Number Of Shares Shorted | 1.25 M | ||||
Price To Book | 0.65 X | ||||
Price To Sales | 50.43 X | ||||
Revenue | 33.49 M | ||||
Gross Profit | 2.6 M | ||||
EBITDA | (28.41 M) | ||||
Net Income | (28.72 M) | ||||
Total Debt | 16.91 M | ||||
Book Value Per Share | 8.28 X | ||||
Cash Flow From Operations | (47.43 M) | ||||
Short Ratio | 17.46 X | ||||
Earnings Per Share | (2.48) X | ||||
Target Price | 21.0 | ||||
Number Of Employees | 82 | ||||
Market Capitalization | 131.16 M | ||||
Total Asset | 105.11 M | ||||
Retained Earnings | (181.31 M) | ||||
Working Capital | 67.59 M | ||||
Net Asset | 105.11 M |
About Artiva Biotherapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Artiva Biotherapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Artiva Biotherapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Artiva Biotherapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Artiva Stock Analysis
When running Artiva Biotherapeutics,'s price analysis, check to measure Artiva Biotherapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Artiva Biotherapeutics, is operating at the current time. Most of Artiva Biotherapeutics,'s value examination focuses on studying past and present price action to predict the probability of Artiva Biotherapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Artiva Biotherapeutics,'s price. Additionally, you may evaluate how the addition of Artiva Biotherapeutics, to your portfolios can decrease your overall portfolio volatility.